Average volume-assured pressure support

Average volume-assured pressure support (AVAPS) is a relatively new mode of noninvasive positive pressure ventilation (NiPPV); only a few studies have been done to compare its effectiveness and safety to bilevel positive airway pressure (BiPAP) in chronic respiratory failure secondary to obesity hypoventilation syndrome, obstructive sleep apnea, chronic obstructive pulmonary disease, and neuromuscular disorders with respiratory muscle weakness. Only six studies were found in PubMed, and these studies had many limitations, especially small sample sizes. This review provides detailed summaries of these studies. These devices require more investigation.


bAckground
Average volume-assured pressure support (AVAPS) and intelligent VAPS (iVAPS) are forms of non-invasive positive pressure ventilation (NiPPV) that adjust the pressure support (PS) to maintain a target average ventilation over several breaths.Both AVAPS and iVAPS adjust PS and the respiratory rate to reach a defined target with the goal of stabilizing the PaCO 2 , which relates directly to alveolar ventilation. 1 With a target tidal volume (e.g., AVAPS), if there is a variance in the respiratory mechanics, especially compliance, which in turn can change the tidal volume, there can be fluctuations in the alveolar ventilation and thus PaCO 2 .By targeting the estimated alveolar ventilation (minute ventilation-estimated dead space ventilation; e.g., iVAPS), variations in respiratory mechanics should not affect alveolar ventilation or PaCO 2 as long as the estimated dead space equals physiologic dead space.The device estimates the anatomic dead space using height.However, patients with lung diseases, such as emphysema, have increased physiologic dead space that would be underestimated using their height, and thus their alveolar ventilation might be much lower than the estimated alveolar ventilation.Thus, emphysema patients may require a higher target alveolar ventilation to achieve adequate alveolar ventilation.The "height" can be entered artificially high in emphysema patients to provide a calculated dead space closer to their physiologic dead space, and iVAPS will provide the desired alveolar ventilation.
Average volume-assured pressure support targets an average tidal volume over several breaths.Typically, the target tidal volume is set based on 6-10 mL/kg ideal body weight.It calculates the average PS provided to the patient over the prior 2 minutes to achieve a particular tidal volume.If average recent ventilation is less than the target volume, inspiratory positive airway pressure (IPAP) for the next breath is increased.Pressure support will change at a rate of 2 cm H 2 O/minute if there is unstable breathing and 1 cm H 2 O/minute if there is stable breathing.The AVAPS-AE model can set This mode of ventilation can help patients with respiratory insufficiency due to neuromuscular and restrictive disorders in which the respiratory effort varies during sleep, 2 patients who need NiPPV during the day, patients with COPD at risk for hypoventilation, and patients with obesity hypoventilation (OHS) who may need compensation based on position and/or sleep stage changes.Because many patients have much worse hypoventilation in REM, BiPAP with fixed PS may provide too much pressure in NREM, which may lead to intolerance or complex sleep apnea and may not provide enough PS in REM to control PaCO 2 levels.
The theoretical benefits of VAPS over BiPAP include maintaining volumes in the setting of altered patient effort based on sleep stage or altered lung mechanics related to position.Less PS while awake may increase comfort and aid sleep onset, reduce the risk of barotrauma, and provide lower pressures most of the time.A randomized trial of iVAPS vs BiPAP found that iVAPS delivered a lower mean PS for oxygenation and transcutaneous PaCO 2 levels and promoted better adherence than BiPAP. 3is literature review provides a detailed summary of studies with AVAPS in patients with chronic respiratory failure, OHS, and COPD with acute hypercapneic exacerbations (also see Table ).

Study goals
• This study tests the hypothesis that AVAPS and the lateral decubitus position in patients with chronic respiratory insufficiency are associated with better sleep efficiency than NIV-PS and the supine position.The secondary aim of the study was to assess the effect of the mode of ventilation, body position, and sleep-wakefulness state on minute ventilation in the same patients.

Methods
• A single blind, randomized, cross-over, prospective trial studied the effects of NIV-PS vs AVAPS on sleep efficiency in twenty-eight patients with chronic respiratory insufficiency (OHS with or without OSA, COPD, neuromuscular disease).
• Thirty-nine patients with the diagnosis of chronic respiratory insufficiency who were currently receiving home ventilation (NIV-PS) for at least two months and were adherent to this therapy ( • Sleep architecture was similar in both modes.However, the supine body position was associated with decreased sleep efficiency when compared to the lateral decubitus position (77.9 ± 22.9% and 85.2 ± 10.5%; P = 0.04).The apnea-hypopnea index was greater during the supine position (median 6.3) than during lateral position (median 0.6). •

Study Goals
• This small prospective randomized crossover trial studied the physiological and clinical effects of AVAPS in 10 OHS patients who did not respond to CPAP.The effects of bilevel pressure ventilation with the spontaneous /timed (BPV with S/T) mode with and without AVAPS over 6 weeks on ventilation pattern, gas exchange, sleep quality, and health related quality of life (HRQL) assessed by severe respiratory insufficiency questionnaire (SRI) were prospectively investigated in a randomized crossover trial.

Methods
• Inclusion criteria: Clinically stable OHS patients with a body mass index of 30 kg/m 2 and daytime hypercapnia (PaCO 2 >45 mm Hg) who had failed to respond to CPAP therapy, had no other cause for their chronic respiratory failure, and were naive to any ventilatory treatment.Exclusion criteria: Patients who had evidence of acute respiratory failure (patients with worsening symptoms during the last 2 weeks, a breathing frequency of 30 breaths/ minute, a pH <7.35, or signs of respiratory infections).Patients who had been intubated during the last 3 months or had received any other form of ventilatory support prior to hospital admission were also excluded from the study.A CPAP responder was defined as a patient who achieved a transcutaneous PaCO 2 level of <45 mm Hg and a respiratory disturbance index (RDI) score of <10 events per hour.
• CPAP nonresponders were discharged from the hospital to home with therapy with BPV-S/T with or without AVAPS following randomization and were readmitted to the hospital after 6 weeks of home therapy.Baseline measurements were repeated, and patients were switched to the alternate mode of BPV-S/T.Measurements were again performed after another period of 6 weeks home therapy following hospital readmission.
• Measurements: pulmonary function tests, daytime blood gas at rest, HRQL measured using the RSI questionnaire, polysomnography, and PtcCO 2 measured during the night at baseline, and during therapy with CPAP, BPV-S/T, and BPV-S/T-AVAPS.Measurements of ventilation were made during therapy with both modes of BPV-S/T using a pneumotachograph to measure volumes, pressures, and respiratory rate.

Results
• Ten patients (mean ± SD; age 53.• Sleep quality and gas exchange substantially improved during nocturnal BPV-S/T therapy compared to baseline, but patients remained hypercapnic overnight even after 6 weeks of BPV-S/T therapy.The addition of AVAPS to BPV-S/T therapy resulted in a significant decrease of PaCO 2 and normalized PaCO 2 during sleep.However, this reduction in PaCO 2 did not lead to further improvements in sleep quality compared to standard BPV-S/T therapy.Daytime PaCO 2 and bicarbonate levels significantly improved following AVAPS therapy only.

Conclusions
• The BPV-S/T mode substantially improved oxygenation, sleep quality, and HRQL in patients with OHS.Average volume-assured pressure support provided additional benefits on ventilation quality and resulted in a bigger decrease in PaCO 2 .However, this did not provide further clinical benefits in sleep quality and HRQL.

Study # 3-Subjective sleep quality during AVAPS ventilation in patients with hypercapnic COPD: a physiological pilot study 4
Study Goals Compliance to ventilation, as measured by mean usage (hours/night), arterial blood gases, comfort, and perceived sleep efficiency (SE by questionnaire) were measured at baseline (T0) and after three (T1) and five (T2) nights over the two periods.

Results
• Measurements were similar between the two treatment periods at baseline.PaCO 2 and comfort improved with both modalities; the SE score significantly improved at T2 with AVAPS (from 5.1 ± 2.0 to 4.1 ± 2.2, P = 0.001) but not with PS (from 5.1 ± 1.7 to 4.7 ± 1.3, P = 0.219).

Conclusions
• No difference in mean usage was found between the two modalities.Mask AVAPS was as comfortable and effective as PS at reducing respiratory acidosis but produced better perceived sleep efficiency in stable hypercapnic COPD patients.
Study # 4-Volume targeted versus pressure support non-invasive ventilation in patients with "super" obesity and chronic respiratory failure: a randomized controlled trial 5 Study Goals • A prospective single-blind randomized controlled trial of AVAPS versus fixed-level PS using a strict protocol done in two centers investigated the effects of the addition of AVAPS to standard BiPAP on the physiological and clinical outcomes in the treatment of stable OHS.
• Measurements: Baseline spirometry, arterial blood gases, anthropometrics including body composition measurements, HRQL assessed by severe respiratory insufficiency questionnaire (SRI), and self-reported sleep comfort.Following randomization, patients underwent respiratory polygraphy, including oximetry and measurement of tcPCO 2 , and supplemental oxygen was provided to patients who met the criteria for daytime hypoxemia.Once established on NIV, patients were discharged and followed up at 3 months.
• The primary outcome was change in daytime arterial PaCO 2 at 3 months.Body composition, physical activity, and HRQL (severe respiratory insufficiency questionnaire, SRI) were secondary outcome measures.

Conclusions
• The study demonstrated no differences between automated AVAPS mode and fixed-level PS mode using a strict protocol setup in patients who were "super" obese.The data suggest that the management of sleep-disordered breathing may enhance daytime activity and promote weight loss in "super" obese patients.

Study # 5-Noninvasive mechanical ventilation with AVAPS in patients with COPD and hypercapnic encephalopathy 6
Study Goals • This study assessed the use of AVAPS in patients with COPD exacerbation and hypercapnic encephalopathy compared to BiPAP S/T Aloud Average Volume-Assured Pressure Support alone upon immediate arrival to the Emergency Department or the ICU.

Methods
• This was a prospective interventional match-controlled study with 22 patients.Eleven patients with COPD exacerbations and hypercapnic encephalopathy with a Glasgow Coma Scale (GCS) <10 and a pH of 7.25-7.35were assigned to receive AVAPS.Eleven patients were selected as paired controls for the initial group by physicians who were unfamiliar with the study, and these patients were managed with BiPAP S/T.Arterial blood gases, GCS, vital signs, and ventilatory parameters were then measured and compared between the two groups.

Results
• There was a statistically significant difference in favor of the AVAPS group in GCS (P = .00001),PaCO 2 (P = .03)and maximum IPAP (P = .005).However, no significant differences in length of stay or days on NIV were observed.

Conclusions
• Average volume-assured pressure support facilitates rapid recovery of consciousness when compared to traditional BiPAP S/T in patients with acute COPD exacerbation and hypercapnic encephalopathy.Average volume-assured pressure support is also a safe strategy of noninvasive ventilatory treatment in patients with exacerbations of COPD and hypercapnic encephalopathy (GCS < 10), with the caveat that these patients should be treated in units with ample experience and under close surveillance.

Study # 6-Efficacy of AVAPS in patients with chronic respiratory failure due to kyphoscoliosis 7
Study Goals • This study evaluated the effectiveness of AVAPS in patients with kyphoscoliosis and chronic respiratory failure.For Outpatient management: There was no difference between the two modalities in improving sleeping efficiency and HRQL in patients with chronic respiratory insufficiency due to OHS with or without OSA, COPD, and neuromuscular disease.There was no difference in mean usage between the two modalities.Mask AVAPS was as comfortable and as effective as PS at reducing respiratory acidosis in stable hypercapnic COPD patients.There were no differences between using AVAPS and fixed-level PS mode in patients who were "super" obese.AVAPS provided additional benefits on ventilation quality, thus resulting in a more efficient decrease of PaCO 2 .However, this did not provide further clinical benefits in sleep quality and HRQL, and this result has uncertain significance.
For Inpatient management: In patients with acute COPD exacerbation and hypercapnic encephalopathy, AVAPS facilitates rapid improvement in the level of consciousness when compared to traditional BiPAP S/T.However, no significant differences in length of stay or days on NIV were observed.AVAPS is a safe strategy of noninvasive ventilatory treatment in patients with exacerbations of COPD and hypercapnic encephalopathy (GCS < 10).These studies do not identify a clinical scenario in which AVAPS has a definite advantage when compared to bi-level pressure support.Patients managed with non-invasive mechanical ventilation need careful monitoring with defined clinical goals to improve outcomes.The exact mode may be less important.
Criticisms common to all these studies include the small sample size and the difficulty with blinding patients to the treatment modality.The higher tidal volumes in the AVAPS groups may not reflect an advantage of AVAPS but rather a poor choice of fixed pressure support in the BiPAP group.recommendAtions 1.For Outpatient management: AVAPS is as safe and as effective as BiPAP but is not superior to it in the management of outpatients with chronic respiratory insufficiency due to OHS with or without OSA, COPD, and neuromuscular disease.
2. For Inpatient management: AVAPS might be preferred over BiPAP for patients with acute COPD exacerbation and hypercapnic encephalopathy as it facilitates more rapid improvement in the level of consciousness.
Aloud Average Volume-Assured Pressure Support a maximum rate of pressure change from 1 cm H 2 O/ minute to 5 cm H 2 O/minute.Expiratory positive airway pressure (EPAP) is fixed with AVAPS, but AVAPS-AE adjusts EPAP as well.Average volume-assured pressure support uses either a fixed rate or auto backup rate set at 2 breaths per minute lower than the rate of the last six spontaneous breaths.

Author Study goal Design Study subjects Results Conclusions Limitations*
*All studies have a small sample size and difficulty with blinding patients to treatment modality.BMI-body mass index; CRF-chronic respiratory failure; yr-year; PS-pressure support AVAPS-average volume assured pressure support; BiPAP-bilevel positive airway pressure; NIMV-non-invasive mechanical ventilation; GCS-Glasgow coma scale; OSA-obstructive sleep apnea, OHS-obesity hypoventilation syndrome; COPD-chronic obstructive pulmonary disease, Vt-tidal volume, NMD-neuromuscular disease, SE-sleep efficiency, SRI-severe respiratory insufficiency.

-Average volume-assured pressure support in obesity hypoventilation 3
Minute ventilation decreased progressively from wakefulness through various stages of sleep (stage 1, stage 2, and REM, P = 0.0001) during BiPAP therapy in the supine position.During BiPAP therapy in the lateral decubitus position, minute ventilation decreased progressively from wakefulness through various stages of sleep (stage 1, stage 2, and REM, P = 0.018).During AVAPS in the supine position, the minute ventilation did not change from wakefulness through the various stages of sleep.